Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abraxis BioScience, Inc.
Abraxis BioScience Reports 14% Revenue Growth to $82.1 Million for the First Quarter of 2008
June 6th, 2008
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, reported unaudited financial results for the first quarter ended March 31, 2008. Net revenue for the first quarter of 2008 increased 14.3 percent to $82.1 million, compared with $71.9 million for the prior year period. Revenue from sales of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) grew 12.8 percent to $79.9 million for the first quarter of 2008 versus $70.9 million for the same period in 2007. Net revenue for the first quarter of 2008 included recognized deferred revenue of $10.2 million, that was initially deferred, relating to the...
Source: Health Business Week (2008-06-06)
|
